Format

Send to

Choose Destination
Mayo Clin Proc. 2006 Mar;81(3):330-4.

Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise.

Author information

1
Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.

Abstract

Linezolid, a novel antimicrobial with activity against gram-positive bacteria including pathogens resistant to traditional antimicrobials, also inhibits monoamine oxidase. This latter property can cause potentially lethal adverse interactions with antidepressant medications. Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome. We review the pharmacology of MAOis and describe 3 clinical situations In which linezolid-selective serotonin inhibitor (SSRI) interactions, actual or potential, figured prominently.

PMID:
16529136
DOI:
10.4065/81.3.330
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center